Genomics and drug discovery - 02/09/11
Abstract |
Genomics, the systematic study of all the genes of an organism, offers a new and much-needed source of systematic productivity for the pharmaceutical industry. The isolation of the majority of human genes in their most useful form is leading to the creation of new drugs based on human proteins, antibodies, peptides, and genes. Human Genome Sciences, Inc, was the first company to use the systematic, genomics approach to discovering drugs, and we have placed 4 of these in clinical trials. Two are described: repifermin (keratinocyte growth factor-2, KGF-2) for wound healing and treatment of mucositis caused by cancer therapy, and B lymphocyte stimulator (BLyS) for stimulation of the immune system. An anti-BLyS antibody drug is in advanced preclinical development for treatment of autoimmune diseases. (J Am Acad Dermatol 2001;45:473-5.)
Le texte complet de cet article est disponible en PDF.Plan
 | Reprint requests: William A. Haseltine, PhD, Human Genome Sciences, Inc, 9410 Key West Ave, Rockville, MD 20850-3338. |
| Published online July 18, 2001. |
Vol 45 - N° 3
P. 473-475 - septembre 2001 Retour au numéro
Article précédent
- Surviving on a balsam-restricted diet: Cruel and unusual punishment or medically necessary therapy?
- Donald V. Belsito
- Clearance can be a realistic expectation of psoriasis treatment
- Paul H. Bowman, John Y.M. Koo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?